FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark

BSE2517.4061.4 (+2.5 %)

PREV CLOSE (Rs.) 2456.00

OPEN PRICE (Rs.) 2479.50

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 19900

TODAY'S LOW / HIGH (Rs.)2432.40 2536.85

52 WK LOW / HIGH (Rs.)1794 2483.3

NSE2515.0055 (+2.24 %)

PREV CLOSE( Rs. ) 2460.00

OPEN PRICE (Rs.) 2460.00

BID PRICE (QTY) 2515.00 (925)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 807816

TODAY'S LOW / HIGH(Rs.) 2431.70 2537.60

52 WK LOW / HIGH (Rs.)1792.6 2484

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

493.61

Dividend Yield(%)

0.10

TTM EPS (Rs.)

7.25

P/E Ratio

347.23

Book Value (Rs.)

881.65

Face Value (Rs.)

MCap (Rs. in Mn)

710472.39

Price/Earning (TTM)

159.59

Price/Sales (TTM)

8.77

Price/Book (MRQ)

2.86

PAT Margin (%)

-2.16

ROCE (%)

-0.76

Incorporation Year : 18-11 1977

Management Info :

Glenn Saldanha - Chairman Glenn Saldanha - Managing Director

Registered Office :

Address : B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone : 022 40189999

Email : complianceofficer@glenmarkpharma.com

Website : www.glenmarkpharma.com

Registrars Details :

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

21Aug Glenmark Pharmaceuticals informs abou
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc..

21Aug Glenmark Pharmaceuticals’ arm launches
Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Pharmaceut..

20Aug Glenmark Pharmaceuticals informs about
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals (Gl..

Financials

	QTR Jun 26	ANNUAL 26
Net Profit	7356.37	-2007.99
Gross Profit	8661.02	-2660.71
Operating Profit	7286.64	18494.21
Net Sales	24349.93	84400.99

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Divi's Laboratories (BSE)

9269.00 (2.42%)

M.Cap (Rs. in Cr)246062.83

Sanofi Cons. Health (BSE)

4213.65 (1.37%)

M.Cap (Rs. in Cr)9704.30

Kwality Pharma (BSE)

3310.25 (1.37%)

M.Cap (Rs. in Cr)3434.78

Haleos Labs (BSE)

1542.00 (2.97%)

M.Cap (Rs. in Cr)466.19

Shareholding Pattern

	PROMOTERS	46.65%
	MUTUAL FUNDS/UTI	16.76%
	NON-INSTITUTION	13.81%
	FI/BANKS/INSURANCE	1.12%
	GOVERNMENT	0.04%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

Mirae Asset Healthc...

6.38

HDFC Pharma and Hea...

5.53

Tata Nifty MidSmall...

4.47

Motilal Oswal Nifty...

4.44

UTI Healthcare Fund...

3.99

Invesco India Midca...

3.97

Bajaj Finserv Healt...

3.51

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22

GLENMARK PHARMACEUTICALS LTD.

Smart Quotes

Attention Investors

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Filing complaints on SCORESEasy & quick

Risk Disclosures On Derivatives